Reference Detail

Ref Type

Journal Article

PMID

(30724426)

Authors

Long F, He Y, Fu H, Li Y, Bao X, Wang Q, Wang Y, Xie C, Lou L

Title

Preclinical characterization of SHR6390, a novel CDK 4/6 inhibitor, in vitro and in human tumor xenograft models.

Journal	Vol	Issue	Date	Pages	Journal Short Title
Cancer science	110	4	2019 Apr	1420-1430	Cancer Sci

URL

Abstract Text

Inhibition of the cyclin-dependent kinase (CDK) 4/6-retinoblastoma (RB) pathway is an effective therapeutic strategy against cancer. Here, we performed a preclinical investigation of the antitumor activity of SHR6390, a novel CDK4/6 inhibitor. SHR6390 exhibited potent antiproliferative activity against a wide range of human RB-positive tumor cells in vitro, and exclusively induced G1 arrest as well as cellular senescence, with a concomitant reduction in the levels of Ser780-phosphorylated RB protein. Compared with the well-known CDK4/6 inhibitor palbociclib, orally administered SHR6390 led to equivalent or improved tumor efficacy against a panel of carcinoma xenografts, and produced marked tumor regression in some models, in association with sustained target inhibition in tumor tissues. Furthermore, SHR6390 overcame resistance to endocrine therapy and HER2-targeting antibody in ER-positive and HER2-positive breast cancer, respectively. Moreover, SHR6390 combined with endocrine therapy exerted remarkable synergistic antitumor activity in ER-positive breast cancer. Taken together, our findings indicate that SHR6390 is a novel CDK4/6 inhibitor with favorable pharmaceutical properties for use as an anticancer agent.

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile	Treatment Approach

Gene Name	Source	Synonyms	Protein Domains	Gene Description	Gene Role

Therapy Name	Drugs	Efficacy Evidence	Clinical Trials
Dalpiciclib	Dalpiciclib	4	0

Drug Name	Trade Name	Synonyms	Drug Classes	Drug Description
Dalpiciclib		SHR 6390\|SHR-6390\|SHR6390	CDK4/6 Inhibitor 13	Dalpiciclib (SHR6390) inhibits CDK4/6, which may lead to cell cycle arrest and tumor growth inhibition (PMID: 30724426).

Gene	Variant	Impact	Protein Effect	Variant Description	Associated with drug Resistance

Molecular Profile	Indication/Tumor Type	Response Type	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
RB1 dec exp	Advanced Solid Tumor	no benefit	Dalpiciclib	Preclinical - Cell culture	Actionable	In a preclinical study, Dalpiciclib (SHR6390) demonstrated limited cytotoxic activity against tumor cell lines with low Rb1 expression in culture (PMID: 30724426).	30724426
RB1 negative	breast cancer	no benefit	Dalpiciclib	Preclinical - Cell culture	Actionable	In a preclinical study, Dalpiciclib (SHR6390) demonstrated little cytotoxic activity against a RB1-negative breast cancer cell line in culture (PMID: 30724426).	30724426
RB1 positive	Advanced Solid Tumor	sensitive	Dalpiciclib	Preclinical - Cell culture	Actionable	In a preclinical study, Dalpiciclib (SHR6390) inhibited CDK4/6-RB pathway signaling, leading to cell cycle arrest and inhibition of proliferation in a panel of RB1-positive tumor cell lines in culture, and tumor growth inhibition in cell line xenograft models (PMID: 30724426).	30724426
RB1 positive	colon cancer	sensitive	Dalpiciclib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Dalpiciclib (SHR6390) inhibited CDK4/6-RB pathway activation, leading to growth inhibition in an RB1-positive colon cancer cell line in culture, and tumor regression in a cell line xenograft model (PMID: 30724426).	30724426